Now showing items 1-13 of 13

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      <h4>Background</h4>Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      Background:Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      <h4>Background</h4>Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits ...
    • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

      James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
      <h4>Importance</h4>The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well ...
    • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 

      Gillessen, S; Omlin, A; Attard, G; de Bono, JS; Efstathiou, E; Fizazi, K; Halabi, S; Nelson, PS; Sartor, O; Smith, MR; Soule, HR; Akaza, H; Beer, TM; Beltran, H; Chinnaiyan, AM; Daugaard, G; Davis, ID; De Santis, M; Drake, CG; Eeles, RA; Fanti, S; Gleave, ME; Heidenreich, A; Hussain, M; James, ND; Lecouvet, FE; Logothetis, CJ; Mastris, K; Nilsson, S; Oh, WK; Olmos, D; Padhani, AR; Parker, C; Rubin, MA; Schalken, JA; Scher, HI; Sella, A; Shore, ND; Small, EJ; Sternberg, CN; Suzuki, H; Sweeney, CJ; Tannock, IF; Tombal, B (2019-12)
    • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 

      Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A; Briganti, A; Bristow, RG; Chi, KN; Clarke, N; Davis, ID; de Bono, J; Drake, CG; Duran, I; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, FY; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Heinrich, D; Higano, CTS; Hofman, MS; Hussain, M; James, N; Kanesvaran, R; Kantoff, P; Khauli, RB; Leibowitz, R; Logothetis, C; Maluf, F; Millman, R; Morgans, AK; Morris, MJ; Mottet, N; Mrabti, H; Murphy, DG; Murthy, V; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Parker, C; Poon, DMC; Pritchard, CC; Reiter, RE; Roach, M; Rubin, M; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Shore, N; Small, E; Smith, M; Soule, H; Sternberg, CN; Steuber, T; Suzuki, H; Sweeney, C; Sydes, MR; Taplin, M-E; Tombal, B; Türkeri, L; van Oort, I; Zapatero, A; Omlin, A (2020-04)
      BACKGROUND:Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...
    • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. 

      Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; Bristow, R; Carver, B; Castellano, D; Chung, BH; Clarke, N; Daugaard, G; Davis, ID; de Bono, J; Borges Dos Reis, R; Drake, CG; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, F; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Higano, CS; James, N; Kantoff, P; Kellokumpu-Lehtinen, P-L; Khauli, RB; Kramer, G; Logothetis, C; Maluf, F; Morgans, AK; Morris, MJ; Mottet, N; Murthy, V; Oh, W; Ost, P; Padhani, AR; Parker, C; Pritchard, CC; Roach, M; Rubin, MA; Ryan, C; Saad, F; Sartor, O; Scher, H; Sella, A; Shore, N; Smith, M; Soule, H; Sternberg, CN; Suzuki, H; Sweeney, C; Sydes, MR; Tannock, I; Tombal, B; Valdagni, R; Wiegel, T; Omlin, A (2018-02)
      <h4>Background</h4>In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level ...
    • MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. 

      Walker, AK; Karaszi, K; Valentine, H; Strauss, VY; Choudhury, A; McGill, S; Wen, K; Brown, MD; Ramani, V; Bhattarai, S; Teo, MTW; Yang, L; Myers, KA; Deshmukh, N; Denley, H; Browning, L; Love, SB; Iyer, G; Clarke, NW; Hall, E; Huddart, R; James, ND; Hoskin, PJ; West, CML; Kiltie, AE (2019-07)
      PURPOSE:Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid ...
    • Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. 

      Hussain, SA; Porta, N; Hall, E; Salawu, A; Lewis, R; Sreenivasan, T; Wallace, J; Crundwell, M; Jenkins, P; Tremlett, J; Huddart, R; James, ND; BC2001 Investigators (2020-12-05)
      <h4>Background</h4>BC2001 demonstrated improved local control with the addition of chemotherapy to radiotherapy in 360 patients with muscle-invasive bladder cancer.<h4>Objective</h4>To establish whether such benefit remained ...
    • Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. 

      Huddart, RA; Hall, E; Lewis, R; Porta, N; Crundwell, M; Jenkins, PJ; Rawlings, C; Tremlett, J; Campani, L; Hendron, C; Hussain, SA; James, ND; BC2001 Investigators (2020-02)
      <h4>Background</h4>BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of ...
    • Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. 

      Pezaro, CJ; Omlin, A; Mastris, K; ANZUP Consumer Advisory Panel; Attard, G; Beer, TM; Chi, KN; Chowdhury, S; Davis, ID; Drake, CG; de Bono, JS; Efstathiou, E; Gravis, G; Higano, CS; Hussain, M; James, N; Logothetis, CJ; Morgans, A; Parker, C; Ryan, CJ; Saad, F; Sartor, O; Small, EJ; Sternberg, CN; Sweeney, CJ; Tannock, I; Tombal, B; Gillessen, S (2017-08)
    • The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). 

      Choudhury, A; West, CM; Porta, N; Hall, E; Denley, H; Hendron, C; Lewis, R; Hussain, SA; Huddart, R; James, N (2017-02)
      Severe chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia ...
    • Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) 

      James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; De Bono, JS; Gale, J; Hetherington, J; Hoskin, PJ; Jones, RJ; Laing, R; Lester, JF; McLaren, D; Parker, CC; Parmar, MKB; Ritchie, AWS; Russell, JM; Strebel, RT; Thalmann, GN; Mason, MD; Sydes, MR (2015-06)